First maraviroc approval is delayed, now the competition - Merck - is catching up.
U.S. regulators will review Isentress, an investigational drug for HIV infection, on a priority basis, and a decision is anticipated by mid-October, Merck & Co. said on Wednesday.
Reuters has the story.
No comments:
Post a Comment